CIDRAP | The US Food and Drug Administration (FDA) announces a multipronged strategy to address antimicrobial resistance (AMR) that emphasizes new measures to spur development of antibiotics and alternative therapies, promote antibiotic stewardship in animal health, advance antibiotic resistance surveillance, and enhance regulatory science. Gottlieb praises ‘push’ incentives to drive innovation but says ‘pull’ incentives are needed as well.